FDA Peptide Update: Category 2 Removals Explained FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them The Blacklisting of Peptides FDA Warning: Hidden Dangers of Smuggled Tirzepatide